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Ankylosing spondylitis;
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DMARDsAbstract Aim of the work: To study the clinical, laboratory and radiographic characteristics of
ankylosing spondylitis (AS) patients living in Qatar.
Patients and methods: Sixty-two consecutive AS patients including 4 Qataris were enrolled. The
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis
Functional Index (BASFI) and AS quality of life (ASQoL) scores were calculated. Inflammatory
markers, human leukocytic antigen-B27 (HLA-B27), plain x-rays and magnetic resonance imaging
of the sacroiliac joint and spine were considered.
Results: Mean age at symptom onset was 25.9 ± 7.3 years and at diagnosis 32.3 ± 8.4 years
with an average delay in the diagnosis of 6.4 years. The male-to-female ratio was 5.2:1. Arabs com-
prised 40.3% while 59.7% were non-Arabs. HLA-B27 was positive in 80.7%. Family history of
spondyloarthritis was present in 16 (25.8%) patients. All patients had inflammatory low back pain.
Peripheral arthritis was observed in 46.8%, heel enthesitis in 37.1% and tenosynovitis in 14.5%
patients. Anterior uveitis occurred in 14.5% patients. Radiological evidence of bilateral sacroiliitis
and spine involvement was observed in 83.3% and 59.7% patients respectively. Mean erythrocyte
sedimentation rate and C-reactive protein were 20.3 ± 14.2 mm/hr and 11.4 ± 11.8 mg/L respec-
tively. Mean BASDAI, BASFI and ASQoL were 3.3 ± 1.8, 2.9 ± 2.1 and 6.5 ± 5.2 respectively.
Twenty-eight patients (45.2%) were maintained on NSAIDs monotherapy, 14.5% were receiving
DMARDs and 40.3% were on biologics.
Conclusion: The characteristics of AS patients in Qatar are revealed. Similar to others, there is
male predominance. Disease activity and functional status were found to be low which may be due
to high frequency of patients receiving biologics.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).0, Street
//dx.doi.
Table 1 Demographic features of the ankylosing spondylitis
patients.
Feature
n (%)
AS patients
(n = 62)
Gender Male
Female
M:F
52 (83.9)
10 (16.1)
5.2:1
Ethnicity Arabs
Egyptian
Jordan
Qatari
Syrian
Lebanese
Tunisian
Iraqi
Sudanese
25 (40.3)
10 (40)
4 (16)
4 (16)
2 (8)
2 (8)
1 (4)
1 (4)
1 (4)
Non Arabs
Indian
Pakistani
Bangladeshi
Nepali
Philippines
Afghani
French
Mauritanian
37 (59.7)
12 (32.4)
8 (21.6)
7 (18.9)
5 (13.5)
2 (5.4)
1 (2.7)
1 (2.7)
1 (2.7)
Age at symptom onset (yr) 25.9 ± 7.3
Age at diagnosis (yr) 32.3 ± 8.4
2 F. Alam et al.1. Introduction
Ankylosing spondylitis (AS) is the prototype of group of
chronic inflammatory diseases called spondyloarthritides
(SpA) [1] and affects predominantly axial skeleton causing
characteristic inflammatory low back pain (iLBP). Sacroiliac
joints are the main joints involved in AS patients while periph-
eral arthritis, enthesitis and tenosynovitis are other muscu-
loskeletal manifestations of this chronic debilitating disease
[2]. The extra articular manifestations of AS include anterior
uveitis, inflammatory bowel disease, cardiac abnormalities
and apical fibrosis of lungs [3,4].
Diagnosis of AS is usually delayed resulting in a gap of sev-
eral years between the onset of symptoms and actual diagnosis
of disease. Delayed diagnosis could be attributed to the low
awareness among non-rheumatologists about AS, increased
frequency of chronic low back pain among population and
the late appearance of radiological evidence of sacroiliitis in
the disease course [5]. Ankylosis of the spine will eventually
result in structural and functional impairments and a decrease
in quality of life (QoL) [6].
A few studies were conducted on the characteristics of AS
in the Middle East [7–10]. The aim of this study was to explore
the characteristics of ankylosing spondylitis in patients living
in Qatar, record the medications used and measure the disease
activity and effect of disease on the QoL.
2. Patients and methods
This cross sectional study was conducted in the outpatient of
the rheumatology department at Hamad General Hospital in
Doha Qatar during the period from March 2014 to February
2015. All those patients who are above age 18, fulfilled the
assessment of SpondyloArthritis International Society (ASAS)
classification criteria for axial spondyloarthritis [11] and signed
the consent form were included in the study. The study con-
forms to the 1995 Helsinki declaration and was approved by
the ethics committee of Hamad General Hospital. Demo-
graphic data and clinical characteristics of disease were taken
from each patient including age at onset of disease, age at diag-
nosis of disease, peripheral joint involvement, occurrence of
enthesitis, tenosynovitis and extra articular manifestations.
Patients were interviewed about their initial treatment and cur-
rent treatment was retrieved from the patients’ files.
The Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) [12], Bath Ankylosing Spondylitis Functional
Index (BASFI) [13] and AS quality of life (ASQoL) question-
naire [14] were calculated at the time of encounter with
patients.
The radiographic data of sacroiliac joint, human leukocytic
antigen-B27 (HLA-B27) status and inflammatory markers
including the erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP), which were done within a week period
before patient interview, were recorded from the electronic
medical record of patients. Results of plain x-rays and mag-
netic resonance imaging (MRI) of spine, which were ordered
by primary physician before interviewing patients, were taken
from electronic medical records of all patients. Squaring of
vertebrae, presence of syndesmophytes, and calcification in
spinal ligaments, bamboo spine, facet joint involvement andPlease cite this article in press as: Alam F et al. Characteristics of Ankylosing Spondy
org/10.1016/j.ejr.2016.09.001bone marrow edema on MRI were considered as part of spinal
involvement due to AS.
Statistical analysis: Categorical and continuous values were
expressed as frequency (percentage) and mean ± SD or med-
ian and range as appropriate. Descriptive statistics were used
to summarize demographic, epidemiological, laboratory,
radiographic and other clinical characteristics of the patients.
Association between two or more qualitative variables (various
clinical and laboratory features with demographic parameters
gender and ethnicity) were compared using Chi-square test or
Fisher’s exact test as appropriate. Quantitative data between
the two independent groups (HLA-B27 positive and negative)
were analyzed and compared using unpaired ‘t’ and Mann–
Whitney U tests as appropriate. Relationships between two
quantitative variables were examined using Pearson’s correla-
tion coefficients. All P values presented were two-tailed, and
P values < 0.05 were considered statistically significant. All
Statistical analyses were done using statistical packages SPSS
22 (SPSS Inc. Chicago, IL).
3. Result
Demographic characteristics of the AS patients are presented
in Table 1. 62 patients were enrolled during a one-year period.
There were 52 males (83.9%) and 10 females (16.1%). Male to
female ratio was 5.2:1.Twenty-five (40.3%) patients were
Arabs and 37 (59.7%) were non-Arabs (Table 1). Mean age
at onset of symptoms was 25.9 ± 7.3 years and mean age at
diagnosis of AS was 32.3 ± 8.4 years with an average delaylitis patients living in Qatar, The Egyptian Rheumatologist (2016), http://dx.doi.
Table 2 Characteristics of the ankylosing spondylitis patients based on gender and ethnicity.
Characteristics
n (%)
Ankylosing spondylitis patients
All
(n = 62)
Gender Ethnicity
Male
(n = 52)
Female
(n = 10)
p Arabs
(n = 25)
Non-Arabs
(n = 37)
p
Peripheral arthritis 29 (46.8) 23 (44.2) 6 (60) 0.36 10 (40) 19 (51.4) 0.38
Bilateral sacroiliitis 60 (96.8) 50 (96.2) 10 (100) 0.53 25 (100) 35 (94.6) 0.24
Tenosynovitis 9 (14.5) 8 (15.4) 1 (10) 0.66 2 (8) 7 (18.95) 0.23
Plantar fasciitis 14 (22.6) 11 (21.2) 3 (30) 0.54 5 (20) 9 (24.3) 0.69
Achilles tendinitis 9 (14.5) 7 (13.5) 2 (20) 0.59 3 (12) 6 (16.2) 0.64
Anterior uveitis 9 (14.5) 6 (11.5) 3 (30) 0.13 6 (24) 3 (8.1) 0.08
HLA-B27 46 (80.7) 41 (85.4) 5 (55.6) 0.04 15 (65.2) 31 (91.2) 0.02
Spinal involvement 37 (59.7) 35 (67.3) 2 (20) 0.005 13 (52) 24 (64.9) 0.31
HLA: human leukocytic antigen. Bold values are significant at p < 0.05
Table 3 Inflammatory markers, disease activity, functional
index and quality of life in ankylosing spondylitis patients.
Parameter AS patients (n = 62)
Mean ± SD Median (Range)
ESR (mm/hr) 20.3 ± 14.2 19 (2–57)
CRP (mg/L) 11.4 ± 11.8 5 (5–62)
BASDAI 3.3 ± 1.8 3.25 (0–6.5)
BASFI 2.9 ± 2.1 2.7 (0–7.2)
ASQoL 6.5 ± 5.2 5 (0–18)
ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein,
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index,
BASFI: Bath Ankylosing Spondylitis Functional Index, ASQoL:
AS quality of life.
Table 4 Pattern of treatment received by the ankylosing
spondylitis patients.
Treatment pattern AS patients (n = 62)
Initial NSAIDs monotherapy
NSAIDs + anti-TNF-a
53 (85.5)
9 (14.5)
Current NSAIDs monotherapy
Anti-TNF-a monotherapy
Anti-TNF-a+NSAIDs
NSAIDs + DMARDs
28 (45.2)
10 (16.1)
15 (24.2)
9 (14.5)
NSAIDs: non-steroidal anti-inflammatory drugs, anti-TNF-a: anti
tumor necrosis factor-a, DMARD: Disease modifying anti-rheu-
matic drug.
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Characteristics of the AS patients based on gender and ethnic-
ity are shown in Table 2. Heel enthesitis was present in 23
(37.1%) patients. Out of this, 9 (14.5%) had Achilles tendinitis
and 14 (22.6%) had plantar fasciitis. Peripheral arthritis was
present in 29 (46.8%); 19 (30.6%) had monoarthritis and 10
(16.1%) had oligoarthritis. The knee joint was the most com-
mon peripheral joint involved (22 patients, 35.5%) while the
ankle joint was involved in 10 (16.1%), wrist in 5 (8.1%),
elbow in 2 (3.2%), metacarpophalangeal joints (MCPs) in 2
(3.2%) and proximal interphalangeal joints (PIPs) in only 1
patient (1.6%). Hip joint was involved in 6 patients (9.7%)
and shoulder joint in only 3 (4.8%) patients. Family history
of spondyloarthritis was present in 16 (25.8%). HLA-B27
was performed in 57 patients (23 Arabs and 34 non Arabs)
and was positive in 46 (80.7%). Three out of four Qatari
patients underwent HLA-B27 testing and only two of them
were positive (66.66%). All patients with anterior uveitis were
HLA-B27 positive.
Radiographic detection of sacroiliitis and spine involve-
ment were observed in 60 patients (96.8%) and in 37
(59.7%) respectively by conventional x-rays and MRI. Bilat-
eral sacroiliitis was found in 60 patients (96.8%), 50 patients
(83.3%) were diagnosed on plain x-rays while 10 patients
(16.7%) were diagnosed on MRI. X-rays of spine were avail-
able in 56 patients (90.32%), at the time of encounter; Lumbar
spine x-rays were reported as abnormal in 32/55 (58.2%)
patients: 21 patients (38.2%) had squaring of vertebrae, 18
(32.7%) had syndesmophytes and spinal ligament calcification.
Thoracic spine x-rays was abnormal in 19/32 (59.37%)
patients; 12 (37.5%) had squaring of vertebrae, 10 (31.3%)
had syndesmophytes and 14 (43.8%) had spinal ligament cal-
cification. Cervical spine x-rays was abnormal in 14/28
(50%) patients; 7 (25%) had squaring of vertebrae, 9
(32.1%) had syndesmophytes and spinal ligament calcification.
Bamboo spine was reported in 7 (12.5%) patients. MRI was
done in only 20 (32.3%) patients; lumbar spine 20 (32.25%),
thoracic spine 5 (8.06%) and cervical spine 4 (6.45%). MRI
spine was reported as abnormal in 12 (60%) patients; bone
marrow edema was present in 8 (40%) patients, facet joint
involvement in 4 (20%) patients and syndesmophytes in 2
(10%) patients. The inflammatory markers (ESR and CRP),Please cite this article in press as: Alam F et al. Characteristics of Ankylosing Spondy
org/10.1016/j.ejr.2016.09.001disease activity, functional index and QoL in the AS patients
are shown in Table 3. Pattern of treatment received by the
AS patients are presented in Table 4. Overall, 25 (40.3%)
patients were currently receiving anti-TNF-a. Out of 25
patients, 11 (44%) were receiving etanercept, 9 (36%) adali-
mumab and 5 (20%) were receiving infliximab. Nine patients
(14.5%) were receiving synthetic DMARDs; 7 (11.3%) were
on sulfasalazine and 2 patients (3.2%) on methotrexate. Char-
acteristic features based on HLA-B27 positivity are presented
in Table 5.litis patients living in Qatar, The Egyptian Rheumatologist (2016), http://dx.doi.
Table 5 Characteristics of ankylosing spondylitis patients
based on HLA-B27 status.
Characteristic
n (%) or mean ± SD
HLA-B27 positivity in AS
patients
P
Positive
(n = 46)
Negative
(n = 11)
Age at symptom onset
(yr)
24.6 ± 7.4 30.2 ± 4.7 0.07
Age at diagnosis (yr) 31.1 ± 6.6 35.4 ± 8.3 0.35
Peripheral arthritis 24 (52.2) 4 (36.4) 0.35
Tenosynovitis 8 (17.4) 0 (.0) 0.14
Plantar fasciitis 11 (23.9) 2 (18.2) 0.68
Achilles tendinitis 7 (15.2) 1 (9.1) 0.6
Anterior uveitis 9 (19.6) 0 (0) 0.11
Family hx SpA 15 (32.6) 0 (0) 0.03
Spine involvement 27 (58.7) 6 (54.5) 0.8
NSAID monotherapy 19 (41.3) 7 (63.6) 0.18
Biologics monotherapy
Biologics plus NSAID
9 (19.6)
11 (23.9)
1 (9.1)
2 (18.2)
0.41
0.68
ESR (mm/hr) 19.8 ± 14.4 21.8 ± 16.04 0.39
CRP (mg/L) 11.4 ± 12.3 12.7 ± 12.2 0.71
ASDAI 2.9 ± 1.7 4.5 ± 1.6 0.67
BASFI 2.7 ± 2.1 3.7 ± 1.9 0.98
ASQoL 6.2 ± 5.4 8.1 ± 4.8 0.18
HLA: human leukocytic antigen, NSAIDs: non-steroidal anti-
inflammatory drugs, ESR: Erythrocyte sedimentation rate, CRP:
C-reactive protein, BASDAI: Bath Ankylosing Spondylitis Disease
Activity Index, BASFI: Bath Ankylosing Spondylitis Functional
Index, ASQoL: AS quality of life. Bold values are significant at
p < 0.05
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This is the first study carried out in Qatar to study the charac-
teristics of patients with ankylosing spondylitis. Other studies,
which were carried out in the Middle East including Saudi
Arabia [8], Jordan [7], Egypt [10] and Iran [9] have described
the different epidemiological and clinical features of AS in
the region. Similar gender ratio with male predominance was
observed in most of the regional and international studies.
Lowest male to female ratio was reported in a study done in
Saudi Arabia (2.8:1) [8] while the highest ratio was observed
in the Jordanian and Korean studies with male to female ratio
of 8.1:1 [7] and 8.6:1 [15] respectively. Male predominance was
also observed in European and South American studies (4.65:1
in a Greek [16] and 5.1:1 in a Brazilian study [17]).
The mean age at onset was similar to those reported in most
of the studies. It was 25.51 years in a Moroccan study [18],
26 years in the Jordanian [19], 23.4 years in Saudi [8], 24.1 in
the Egyptian [10], 23.6 in the Indian [20] and 22.3 years in
the Korean study [15]. Similar result was seen in a study done
in Portugal (26.5 years) [21] while it was higher in the study
conducted in Greece (30.5 years) [16]. The mean delay in diag-
nosis in this study was 6.4 years in comparison with 3.9 years
in Saudi Arabia [8], 4.6 years in Morocco, 6.2 years in Iran
and 7.6 years in Portugal [21].
Peripheral arthritis was present in 29 patients (46.8%) in
our study compared to 33% in Saudi Arabia [8], 34% in Jor-
dan [7] and 36.2% among Moroccan [18].Mohammad et al. [9]
reported an increased occurrence of peripheral arthritis in Ira-
nian population (63.2%); the knees were affected in 34.7%,Please cite this article in press as: Alam F et al. Characteristics of Ankylosing Spondy
org/10.1016/j.ejr.2016.09.001ankles in 19.4%, wrists in 6.1% and elbows in 3.06%. Our
study showed a similar pattern with involvement of knee in
35.5%, ankle in 16.1%, wrist in 8.1% and elbow in 3.2%.
The prevalence of peripheral arthritis was reported to be
57% in Latin America and 42% in Europe [22] while in Greece
was as a high as 72% [23].
Anterior uveitis is the most common extra articular symp-
toms in AS. It was observed in 14.5% of our patients,
44.9% in Iranian population [9], 13% in Jordanians [7],
6.8% in Moroccan [18] patients and 14.3% in a Brazilian
[17] population. Benegas et al. [22] reported a prevalence of
24% in European patients and 22% in those from Latin Amer-
ica. The heterogeneity in the prevalence of anterior uveitis
could be due to variation in geographical prevalence of
HLA-B27, differences in data collection and definition of the
occurrence of uveitis. Systematic review and meta-analysis
[24] showed that the prevalence of anterior uveitis was
25.8% in AS patient. The prevalence estimates were the high-
est in North America (35.2%) and Europe (29.3%), and lower
in Asia (21.4%) and Latin America (20.1%). In a study con-
ducted by Essers et al. [25], the prevalence of anterior uveitis
was 18% and 89.7% of these patients were HLA-B27 positive.
In contrast to this, in our study all patients with anterior uvei-
tis were HLA-B27 positive.
If left untreated, AS will lead to permanent disability. Var-
ious treatment options are available in today’s modern era.
These include NSAID and disease modifying drugs. Anti
TNF drugs have revolutionized the treatment of AS. A study
conducted in Morocco [18], showed that 52.6% of patients
had been treated with DMARDs. More patients were main-
tained on synthetic DMARDs than biological DMARDs;
50% of patients were using sulfasalazine, 15.5% methotrexate
and 2.6% anti-TNF. In another study [22] treatment options
were compared between European (EU) and Latin American
(LA) patients; NSAID were used in 75% of the EU patients
but in 89% of the LA, MTX 10% versus 34%, SSZ 19% ver-
sus 32% and anti-TNF-a 15% versus 14% respectively. Study
from Portugal [21] showed that majority of AS cases were tak-
ing NSAIDs (79.1%). DMARDs were being used by 48.5%,
sulfasalazine monotherapy by 30.9% of the patients,
methotrexate monotherapy by 8.4% and 6% were taking both.
TNF-blockade was being used by 22% of the patients. In com-
parison, less number of patients in our study were receiving
synthetic DMARD (14.5%), while high number of patients
were receiving anti- TNF-a (40.3%). The health system pro-
vides free health care for the nationals and nominal fee for
the expatriates residing in Qatar. This is one of the reasons
why many patients are able to receive anti-TNF-a when
indicated.
A study on 34 Egyptian AS patients revealed a mean BAS-
DAI of 4.2 ± 2.1 and BASFI 5.1 ± 2.4 [10] and in a more
recent study even higher scores 5.7 ± 1.8 and 5.8 ± 1.4 respec-
tively were reported on 44 AS patients [26]. Hajialilo et al. [27]
divided Iranian AS patients in two groups on basis of diagno-
sis delay. BASDAI in early diagnosis was 3.3 ± 0.9 years and
in late diagnosis was 3.6 ± 0.7 years. On the other hand,
BASFI was 3.3 ± 1 and 4.1 ± 0.7 on early and late diagnosis
respectively. In a study conducted by Reilly et al. [28] the mean
baseline BASDAI score for 315 AS patients was 6.3 ± 1.7 and
the ASQoL score was 10.3 ± 4.3. The BASDAI was 4.2 ± 2.3
and BASFI was 4.1 ± 2.7 in patients from Portugal [21]. The
disease activity, functional score and QoL were lower in ourlitis patients living in Qatar, The Egyptian Rheumatologist (2016), http://dx.doi.
Characteristics of ankylosing spondylitis patients 5study patients as the BASDAI was 3.3 ± 1.8, mean BASFI
was 2.9 ± 2.1 and the mean ASQoL score was 6.48 ± 5.2.
Higher numbers of our study patients were receiving biologics
which explains the lower values.
Inflammatory markers in this study, ESR and CRP were
comparable to those in studies from Morocco [29] and Korea
[15]. The levels were not higher in our study patients, which
support the theory that inflammatory markers might not be
elevated in patients with clinically active disease.
Prevalence of HLA-B27 in AS patients in Qatar was
reported as 69% in a previous study [30] as 82% of Qataris
were HLA-B27 positive. In our study the HLA-B27 positivity
was 80.7% and only 2 out of 3 Qataris were positive. Data
from Arabs and Asian countries regarding prevalence of
HLA-B27 in AS patients are variable. It ranges from 58 to
98%. In Jordan, 72% [7] to 81% [19] of AS patients were
HLA-B27 positive. 67% of AS patient in Saudi Arabia [8],
82.6% in Kuwait [31], 73.4% in Iran [9] and 92.9% in India
were HLA-B27 positive. Two studies from Egypt revealed an
HLA-B27 positivity of and 82% [26] and 86.7% [32] although
a lower frequency was also reported (58.6%) [10]. The highest
prevalence was observed in Korea (98.5%)[15]. From Euro-
pean countries, HLA-B27 positivity in AS patients was
reported as 80.5% in a study from Portugal [21] and 90% in
Greek male patients [23]. The higher number of HLA-B27 pos-
itive patients on biologics could explain the lower disease activ-
ity compared to negative patients.
Our study has limitations including the sample size which is
relatively small compared to some other cited studies but still is
larger than several other studies from close countries with
much bigger populations. Furthermore some data were miss-
ing from the patient’s file or some test were not done including
the HLA-B27 (57 out of 62) and some radiographic studies as
these were ordered by the primary rheumatologist who is fol-
lowing the patient but all the other data which include the
demographic, clinical, disease activity scores and laboratory
data were collected in the day of the interview to ensure the
completeness of these information. In addition to the above
limitations the study disclosed that only 25 of the total 62
patients were of Arab origin but this reflects the true composi-
tion of the population. Overall we believe that this study
despite these limitations will contribute to the knowledge
about the characteristics of AS patients in this part of the
world. Certainly a larger joint study from Middle East coun-
tries will be very valuable.
In conclusion, this study provides profile of AS in Qatar.
Characteristics of AS patients in Qatar are similar to other
Middle East countries. A significant proportion of patients
has peripheral arthritis. All patients with anterior uveitis are
HLA-B27 positive. Disease activity and functional scores are
low in this study because of a higher percentage of patients
receiving anti-TNF-a.
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